Europe - EPA:GNFT - FR0004163111 - Common Stock
The current stock price of GNFT.PA is 3.68 EUR. In the past month the price increased by 1.6%. In the past year, price decreased by -30.96%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 22.02 | 355.96B | ||
1ABBV.MI | ABBVIE INC | 21.97 | 355.08B | ||
AMG.DE | AMGEN INC | 13.58 | 137.77B | ||
GIS.DE | GILEAD SCIENCES INC | 15.17 | 125.94B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 24.14 | 90.61B | ||
ARGX.BR | ARGENX SE | 93.39 | 42.69B | ||
1AE.DE | ARGENX SE | 93.04 | 42.53B | ||
1INSM.MI | INSMED INC | N/A | 29.80B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.76B | ||
IDP.DE | BIOGEN INC | 9.18 | 18.63B | ||
1EXAS.MI | EXACT SCIENCES CORP | N/A | 9.34B | ||
0QF.DE | MODERNA INC | N/A | 9.26B |
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 180 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
GENFIT
Parc Eurasante 885 avenue Eugene Avinee
LOOS HAUTS-DE-FRANCE FR
Employees: 180
Phone: 33320164000
The current stock price of GNFT.PA is 3.68 EUR. The price decreased by -1.76% in the last trading session.
The exchange symbol of GENFIT is GNFT and it is listed on the Euronext Paris - Matif exchange.
GNFT.PA stock is listed on the Euronext Paris - Matif exchange.
13 analysts have analysed GNFT.PA and the average price target is 8.93 EUR. This implies a price increase of 142.53% is expected in the next year compared to the current price of 3.68. Check the GENFIT stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GENFIT (GNFT.PA) has a market capitalization of 184.01M EUR. This makes GNFT.PA a Micro Cap stock.
GENFIT (GNFT.PA) currently has 180 employees.
GENFIT (GNFT.PA) has a support level at 3.54 and a resistance level at 3.84. Check the full technical report for a detailed analysis of GNFT.PA support and resistance levels.
The Revenue of GENFIT (GNFT.PA) is expected to decline by -8.28% in the next year. Check the estimates tab for more information on the GNFT.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GNFT.PA does not pay a dividend.
GENFIT (GNFT.PA) will report earnings on 2025-11-20.
GENFIT (GNFT.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).
ChartMill assigns a technical rating of 4 / 10 to GNFT.PA. When comparing the yearly performance of all stocks, GNFT.PA is a bad performer in the overall market: 88.93% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to GNFT.PA. GNFT.PA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months GNFT.PA reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS decreased by -327.32% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -17.89% | ||
ROE | -73.87% | ||
Debt/Equity | 0.09 |
13 analysts have analysed GNFT.PA and the average price target is 8.93 EUR. This implies a price increase of 142.53% is expected in the next year compared to the current price of 3.68.
For the next year, analysts expect an EPS growth of 15.82% and a revenue growth -8.28% for GNFT.PA